Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cantuzumab ravtansine
- Development stage
- Phase 1
- Lead developer
- ImmunoGen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cantuzumab ravtansine is an antibody-drug conjugate (ADC) developed for the treatment of cancers. It consists of a humanized monoclonal antibody, cantuzumab (huC242), which targets Tumor-associated carbohydrate antigen CanAg, a glycoform of MUC1 that is overexpressed in various tumors such as those of the pancreas, colon, and biliary tract. The antibody is linked via a hindered disulfide linker to the cytotoxic agent DM4 (ravtansine), a maytansinoid that disrupts microtubule assembly by binding tubulin. Upon binding to CanAg on tumor cells and internalization, the ADC releases DM4 intracellularly, leading to inhibition of cell division and induction of apoptosis. Cantuzumab ravtansine was primarily developed by ImmunoGen for indications including gastric cancer and solid tumors but development has been discontinued[1][2][5][6][7].
- Other names
- cantuzumab ravtansine
02
Targets
TUBB (Tubulin (alpha and beta subunits))CanAg (CA242/CanAg glycoform of MUC1)
Beyond the preview
Go deeper on cantuzumab ravtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cantuzumab ravtansine.